Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trialEsther Natalie Olíva, Roberto Latagliata, Flavia Salvi et al.|The Lancet Haematology|2017Cited by 163
Quality of life and physicians' perception in myelodysplastic syndromes.Oliva En, Spiriti Ma, Carlo Finelli et al.|PubMed|2012Cited by 51
Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Results on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, TrialEsther Natalie Olíva, Roberto Latagliata, Valeria Santini et al.|Blood|2015Cited by 13